Awards & Recognition

HOPA Award of Excellence

The HOPA Award of Excellence recognizes a HOPA member who has made a significant, sustained contribution to or provided excellent leadership in developing or supporting hematology/oncology pharmacy.

2019    George Carro, RPh MS BCOP

2018    R. Donald Harvey, PharmD BCOP FCCP FHOPA

2017    Terri G. Davidson, PharmD BCCP BCOP FASHP

2016    Niesha L. Griffith, MS RPh FASHP

2015    David W. Henry, MS BCOP FASHP

2014    Rowena N. Schwartz, PharmD BCOP

2013    Robert Ignoffo, PharmD FASHP FCSHP

2012    Susan Goodin, PharmD

2011    Jim Koeller, MS

2010    Val R. Adams, PharmD FCCP BCOP

2009    Barry R. Goldspiel, PharmD BCOP BCPS FASHP FISOPP

2008    Carol M. Balmer, PharmD BCOP

2007    Jane M. Pruemer, PharmD BCOP FASHP

2006    Judy L. Chase, PharmD FASHP;

           Amy W. Valley, PharmD BCOP

2005    LeAnne D. Kennedy, BCOP

HOPA Diversity, Equity, and Inclusion Award

2022    Maurice Alexander, PharmD, BCOP & Britny R. Brown, PharmD, BCOP

HOPA New Practitioner Award

The HOPA New Practitioner Award recognizes a HOPA member early in their career who has made a significant contribution to developing or supporting clinical hematology/oncology pharmacy services.

2022    Kathryn Maples, PharmD, BCOP

2021    Justin Arnall, PharmD, BCOP

2020    Kirollos S. Hanna, PharmD, BCPS, BCOP & Megan N. Dillaman, PharmD, BCOP

2019    Megan May, PharmD BCOP

2018    Alexandra Shillingburg, PharmD BCOP

2017    Amber Bradley Clemmons, PharmD BCOP

2016    Kristin Held Wheatley, PharmD BCOP

2015    Patrick J. Kiel, PharmD BCPS BCOP

2014    Robert S. Mancini, PharmD BCOP

2013    Steve Stricker, PharmD MS BCOP

2012    Daniel Zlott, PharmD BCOP

2011    Trevor McKibbin, PharmD MS BCPS

2010    LeAnn Best Norris, PharmD BCPS BCOP

2009    Julianna Burzynski, PharmD BCPS BCOP

2008    Janet Espirito, PharmD BCOP

HOPA Patient Advocacy Award

The HOPA Patient Advocacy Award recognizes a HOPA member who demonstrates leadership and collaboration while advocating for outstanding patient care.

2022    Sarah E. Wheeler, PharmD, BCOP

2021    Megan Langer, PharmD, BCOP

2020    Kathy Hogan Edwards, PharmD, BCPS, BCOP

2019    Ashley Glode, PharmD BCOP

2017    Kerry Parsons, PharmD BCOP FHOPA

2016    Benyam Muluneh, PharmD BCOP CPP

2015    Rowena N. Schwartz, PharmD BCOP

2014    Sarah S. Hudson-DiSalle, PharmD RPh

HOPA Technician Award

The HOPA Hematology/Oncology Technician Award recognizes a HOPA technician member who demonstrates excellence in his/her work and a commitment to hematology/oncology pharmacy practice in an organized healthcare setting.

2022    Alicia M. Holguin, CPhT & May Lo

2021    Emily Zimdars, BA, CPhT & Jessica Turner, CPhT

2020    Alexamil Rodriguez, CPhT

2019    Amanda Pate, CPhT

2018    Desiree Rolniak, CPhT

2017    Cheryl Hyk, MA CPhT

2016    Edward D. Gormley, BS CPhT

2011    Tanja Monroe

2010    Therese McGrain, CPhT

2009    Jeanne Anderson, CPhT

2008    Kenneth Grohgans, CPhT

2007    Darrell Clarke, CPhT;

           Anne Hameed, CPhT

HOPA Volunteer Award

The HOPA Volunteer Award recognizes the time, talent and energy of a HOPA member who contributes significant volunteer service to the organization.

2022    Mallika P. Patel, PharmD, CPP

2020    Eve-Michell Segal, PharmD, BCOP

2019    Ila Saunders, PharmD BCOP

HOPA Leadership Award

The HOPA Leadership Award recognizes pharmacy practitioners who have distinguished themselves by demonstrating superior leadership skills when challenged by a specific opportunity, for their institution, HOPA, or the pharmacy profession that produced/culminated in a significant outcome. As a result they will have advanced oncology pharmacy practice, or made positive changes that benefit patients, students, or colleagues in hematology/oncology pharmacy.

2021    Ali McBride, PharmD, MS

HOPA Oncology Pharmacy Practice Literature Award

This award recognizes an author who has written an article, other than scientific research, that contributes significantly to the betterment of the hematology/oncology pharmacy profession and describes innovations in community, hospital, or healthcare system hematology/oncology pharmacy practices that are applicable beyond the practice site where they were developed and/or evaluated.

2022 Shannon Hough, PharmD, BCOP

Hough S, McDevitt R, Nachar VR, Kraft S, Brown A, Christen C, Frame D, Smerage JB. Chemotherapy Remote Care Monitoring Program: Integration of SMS Text Patient-Reported Outcomes in the Electronic Health Record and Pharmacist Intervention for Chemotherapy-Induced Nausea and Vomiting. JCO Oncol Pract. 2021 Feb 3:OP2000639. doi: 10.1200/OP.20.00639

2021 Grant Lee, PharmD

Lee GW, Mathur AD, Andrick BJ, Leese E, Zally D, Gatson NTN. Pharmacist value-added to neuro-oncology subspecialty clinics: a pilot study uncovers opportunities for best practices and optimal time utilization. J Oncol Pharm Pract. 2020 Sep 17;1078155220957738. PubMed PMID: 32938297.

2020 Jacqueline L. Olin, M.S., PharmD, BCPS

Olin JL, Klibanov O, Chan A, Spooner LM. Managing pharmacotherapy in people living with HIV and concomitant malignancy. Ann Pharmacother 2019 Aug;53(8):812-832. doi: 10.1177/1060028019833038. Epub 2019 Feb 15.

2019 Julianne Orr, PharmD BCOP

Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, Deremer D. Randomized, Placebo-Controlled, Phase III Trial of Fosaprepitant, Ondansetron, Dexamethasone (FOND) Versus FOND Plus Olanzapine (FOND-O) for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients with Hematologic Malignancies Receiving Highly Emetogenic Chemotherapy and Hematopoietic Cell Transplantation Regimens: The FOND-O Trial. Biology of Blood and Marrow Transplantation. 2018;24(10):2065–71.

2017 Karen Sweiss, PharmD

Sweiss K, Patel S, Culos K, Oh A, Rondelli D, Patel P. Melphalan 200 mg/m2 in patients with renal impairment is associated with increased short term toxicity but improved response and longer treatment-free survival. Bone Marrow Transplant 2016; e-pub ahead of print 16 May 2016; doi:10.1038/bmt.2016.136.

2016    Ginah Nightingale, PharmD BCOP

Nightingale G, Hajjar E, Swartz K, et al. Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol. 2015;33:1453-1459.

2015    Joseph S. Bubalo, PharmD BCOP BCPS

Bubalo J, Carpenter PA, Majhail N, Perales MA, Marks DI, Shaughnessy P, Pidala J, Leather HL, Wingard J, Savani BN. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. Biol Blood Marrow Transplant. 2014 May;20(5):600-16. doi:10.1016/j.bbmt.2014.01.019. Epub 2014 Jan 23.

2014    Ali McBride, PharmD MS BCPS BCOP

McBride A, Lathon S, Boehmer L, Augustin KM, Butler SK, Westervelt P. Comparative Evaluation of Single Fixed Dosing and Weight-Based Dosing of Rasburicase for Tumor Lysis Syndrome. Pharmacotherapy. 2013;33(3):295-303.

2013    Kamakshi V. Rao, PharmD BCOP CPP

Strother RM, Rao KV, Gregory KM, Jakait B, Busakhala N, Schellhase E, Pastakia S, Krzyzanowski M, Loehrer PJ. The oncology pharmacy in cancer care delivery in a resource-constrained setting in western Kenya. J Oncol Pharm Pract 2012. Jan 16

2012    Kristine R. Crews, PharmD, BCPS

Crews KR, Cross SJ, McCormick JN, Baker DK, Molinelli AR, Mullins R, Relling MV, Hoffman JM. Development and implementation of a pharmacist-managed clinical pharmacogenetics service. Am J Health Syst Pharm 68:143-50, 2011

2010    Brian Crandell, PharmD, BCOP

O'Bryant CL, Crandell BC. Community pharmacists’ knowledge of and attitudes toward oral chemotherapy. J Am Pharm Assoc. 2008;48:632-9.

HOPA Basic Science and Clinical Research Literature Award

This award recognizes an author who has written an important scientific article describing hematology/oncology basic science and/or translational research or clinical trials evaluating drug efficacy and/or safety.

2022    Lydia Benitez, PharmD, BCOP

Benitez LL, Perissinotti AJ, Rausch CR, Klaus J, Clark SM, Filtz M, Ratermann K, Treptow C, Griffin S, Olson M, Crain M, Kadia T, Pettit K, Burke PW, Bixby DL, Marini BL. Multicenter comparison of high-dose cytarabine-based regimens versus liposomal daunorubicin and cytarabine (CPX-351) in patients with secondary acute myeloid leukemia. Leuk Lymphoma. 2021 Apr 8:1-9. doi: 10.1080/10428194.2021.1907378. Epub ahead of print. PMID: 33830856.

2021    Victoria Nachar, PharmD, BCOP

Hoylman E, Brown A, Perissinotti A, et al. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2020 Mar;61(3):691-698

2020    Daniel J. Crona, PharmD, PhD, CPP

Crona DJ, Skol AD, Leppänen V-M, Glubb DM, Etheridge AS, Hilliard E, Peña C, Peterson Y, Klauber-DeMore N, Alitalo KK, Innocenti F. Novel genetic determinants of survival in renal cell carcinoma patients treated with sorafenib: a clinical and translational experimental study. Cancer Res. 2019 Jan; 79(1):231-241. PMCID: PMC6541205.

2019    Judith A. Smith, BS PharmD BCOP CPHQ FCCP FISOPP

Cotton S, Brown RE, Nugent EK, Robazetti SC, Berens PD, Smith JA. Quality Improvement to Demonstrate the Lack of Reliability of the Human Papillomavirus mRNA Assay to Identify Women With Latent Human Papillomavirus Infections. Obstetrics & Gynecology. 2018Apr;131(4):681–7.

2016    Meghana V. Trivedi, PharmD PhD BCOP

Do T, Medhekar R, Bhat R, Chen H, Niravath P, Trivedi MV. The risk of febrile neutropenia and need for G-CSF primary prophylaxis with the docetaxel and cyclophosphamide regimen in early-stage breast cancer patients: a meta-analysis. Breast Cancer Res Treat. 2015 Oct;153(3):591-7. Epub 2015 Sep 4.

2015    David J. Reeves, PharmD BCOP

Reeves DJ, Moore ES, Bascom D, Rensing B. Retrospective evaluation of methotrexate elimination when co-administered with proton pump inhibitors. Br J Clin Pharmacol. 2014 Sep;78(3):565-71. Doi: 10.1111/bcp.12384 PMID: 24646036

2014    Casey B. Williams, PharmD BCOP

Williams CB, Kambhampati S, Fiskus W, Wick J, Dutreix C, Ganguly S, Aljitawi O, Reyes R, Fleming A, Abhyankar S, Bhalla KN, McGuirk JP. Preclinical and Phase I Results of Decitabine in Combination with Midostaurin (PKC412) for Newly Diagnosed Elderly or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia. Pharmacotherapy. 2013 Jun 24. doi: 10.1002/phar.1316.

2013    Wendelin Nelson, PharmD BCOP

Nelson WK, Formica RN, Cooper DL, Schwartz PE, Rutherford TJ. An analysis of measured and estimated creatinine clearance rates in normal weight, overweight, and obese patients with gynecologic cancers. J Oncol Pharm Pract 2012;18(3):323-332.

2012    Cindy O'Bryant, PharmD BCOP FCCP

O'Bryant CL, Haluska P, Rosen L, Ramanathan RK, Venugopal B, Leong S, Boinpally R, Franke A, Witt K, Evans J, Belani C, Gail Eckhardt S, Ramalingam S. An open-label study to describe pharmacokinetic parameters of erlotinib in patients with advanced solid tumors with adequate and moderately impaired hepatic function. Cancer Chemother Pharmacol. 2011 Sep 22

2011    Jacob K. Kettle, PharmD

Kettle JK, Grauer D, Folker TL, et al. Effectiveness of exogenous albumin administration for the prevention of ifosfamide-induced encephalopathy. Pharmacotherapy. 2010;30(8):812-817.

2010    LeAnne Kennedy, PharmD, BCOP

Kennedy LD, Case LD, Hurd DD, Cruz JM, Pomper GJ. A prospective, randomized, double-blind controlled trial of acetaminophen and diphenhydramine pretransfusion medication versus placebo for the prevention of transfusion reactions. Transfusion. 2008;48:2285-91.

HOPA Clinical Practice Literature Award

2009    Stacy S. Shord, PharmD, BCOP

             Sandra Cuellar, PharmD, BCOP

Shord SS, Hamilton JM Jr, Cuellar S. Parenteral iron with erythropoiesis-stimulating agents for chemotherapy-induced anemia. J Oncol Pharm Pract. 2008;14:5-22.

2007    Donald A. Hutcherson, RPh

Hutcherson DA, Gammon DC, Bhatt MS, Faneuf M. Reduced-dose rasburicase in the treatment of adults with hyperuricemia associated with malignancy. Pharmacotherapy. 2006;26:242-247.

2006    Susan Goodin, PharmD, BCOP

 Blower P, de Wit R, Goodin S, Aapro M. Drug-drug interactions in oncology: Why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55:117-142

HOPA Clinical Practice Award

The HOPA Clinical Practice Award recognizes a HOPA member who has made a significant contribution to or has provided leadership to developing or supporting an innovative clinical hematology/oncology pharmacy service.

2007    Dominic A. Solimando Jr, MA, RPh, BCOP, FAPhA, FASHP

2006    David Baribeault, RPh, BCOP

             Sachin Shah, PharmD, BCOP